|Bid||4.0700 x 800|
|Ask||4.0900 x 1200|
|Day's range||4.0500 - 4.3200|
|52-week range||3.1450 - 10.9800|
|Beta (5Y monthly)||1.05|
|PE ratio (TTM)||N/A|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.00|
Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.
Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.
Immunovant plans to initiate two placebo-controlled Phase 3 clinical trials of batoclimab in thyroid eye disease (TED) in the second half of calendar year 2022 with top-line data expected for both in the first half of calendar year 2025Immunovant estimates annual addressable U.S. TED population for a new mechanism of action to be 8,000-18,000 patientsImmunovant on track to initiate pivotal Phase 3 clinical trial of batoclimab in myasthenia gravis (MG), by the end of June 2022Cash balance of $494